Patient P-01564
Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
94%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 43 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 57 ME-01 recommended — Monitoring Escalation ME-01
- Day 58 Patient accepted — Started ME-01 in the companion
- Day 60 GI-04 recommended — GI Support Protocol GI-04
- Day 61 Patient declined — Not now
- Day 61 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 43.
Primary contributors, last 14 days
- GI instability-16
- Nutritional resilience+13
- Inflammatory activity-12
- Treatment adherence-8
- Toxicity-2
What helped?
- Monitoring Escalation ME-01Day 57Result: deterioration detected before clinical escalation
- GI Support Protocol GI-04Day 60Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- WearableSleep 5.2 h, below personal baseline
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 51
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 29/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 79 bpm
- WearableShort sleep window
- Inflammatory signalling ↓25
- BloodInflammatory load index 55
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.3 · butyrate capacity 29/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 35 ms
- Sleep
- 5.3 h
- Steps
- 6,698
- Resting HR
- 79 bpm
Daily log: GI score 62, nutritional resilience 40, adherence 41.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01605 | 57% | S14 | ME-01 | improved | 41 |
| P-01830 | 56% | S14 | — | — | 44 |
| P-01656 | 55% | S14 | ME-01 | improved | 41 |
| P-01646 | 54% | S14 | GI-04 | no change | 42 |
| P-01728 | 53% | S14 | SC-12 | improved | 41 |
| P-01834 | 53% | S14 | NP-02 | improved | 44 |
| P-01732 | 52% | S14 | ME-01 | improved | 45 |
| P-01751 | 52% | S14 | ME-01 | improved | 48 |
| P-01463 | 51% | S14 | NP-02 | no change | 41 |
| P-01598 | 50% | S14 | GI-04 | no change | 45 |
| P-01396 | 49% | S14 | GI-04 | worsened | 51 |
| P-01655 | 49% | S14 | GI-04 | no change | 29 |